Conmed Posts Mixed Bag Q4 Earnings, Issues FY22 Outlook

CONMED Corporation CNMD reported Q4 FY21 adjusted EPS of $1.07, compared to $0.84 a year ago, and better than the consensus of $1.06.

  • Sales for the quarter rose 8.4% Y/Y to $273.97 million, missing the consensus of $278.76 million.
  • Domestic revenue increased 5.0% Y/Y, and International revenue increased 12.7% as reported and 14.3% in constant currency.
  • The gross margin improved from 53.6% to 56.9%, and the operating margin increased from 9.8% to 13.6%.
  • "Our 2021 financial performance finished favorably against the expectations we set at the beginning of the year despite the challenging environment," noted Curt Hartman, CONMED's Chair of the Board, President & CEO.
  • Guidance: Looking forward to FY22, CONMED expects adjusted earnings of $3.60 - $3.85 per share (consensus of $3.74) and revenues of $1.075 billion - $1.125 billion, compared to the consensus of $1.11 billion.
  • Price Action: CNMD shares are up 1.74% at $124.00 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!